linjc16/ctgov huggingface dataset:
Gait Evaluation of Experienced Below Knee Amputees

Study Overview
=================
Brief Summary
-----------------
Post traumatic amputees with an experience of over 3 months of prosthesis use at home, without any known difficulty using the prosthesis and without stump pathology, using no assistive devices, will be examined in a 3 D computerized gait laboratory. Kinematic and kinetic parameters of gait will be obtained.

Official Title
-----------------
Gait Evaluation of Experienced Post Traumatic Below Knee Amputees

Conditions
-----------------
Amputations, Traumatic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post traumatic trans tibial amputees No stump pathology No assistive devices No technical difficulty Exclusion Criteria: Vascular or DM background Stump pathology Gait difficulties Assistive device

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Amputation, trans tibial, prosthesis, motion analysis
Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy

Study Overview
=================
Brief Summary
-----------------
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in patients (pts) with hematologic malignancies. As culture-based methods only yield results in a minority of patients, using non-culture-based methods for detection of aspergillosis in clinical specimens becomes increasingly important. Analyzing bronchoalveolar lavage (BAL) samples with polymerase chain reaction (PCR) is promising, however, the influence of current antifungal drugs on the performance of this diagnostic tool remains controversial. The aim of the trial is to elucidate on the performance of BAL PCR under antifungal treatment.

Detailed Description
-----------------
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in patients (pts) with hematologic malignancies. As culture-based methods only yield results in a minority of patients, using non-culture-based methods for detection of aspergillosis in clinical specimens becomes increasingly important. Analyzing bronchoalveolar lavage (BAL) samples with polymerase chain reaction (PCR) is promising, however, the influence of current antifungal drugs on the performance of this diagnostic tool remains controversial. The aim of the trial is to elucidate on the performance of BAL PCR under antifungal treatment. Patients with high risk of invasive aspergillosis and lung infiltrates are sampled via BAL, the sample is analyzed for fungal DNA by Apsergillus specific PCR. Clinical data including treatment data is assessed and evaluated.

Official Title
-----------------
Diagnosing Invasive Aspergillosis by PCR Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy

Conditions
-----------------
Invasive Aspergillosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: immunocomprimised patients with high risk of invasive aspergillosis and lung infiltrates informed consent Exclusion Criteria: Children under the age of 5 years Informed consent not available

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| proven or probable aspergillosis<br> | |
| possible aspergillosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Glecaprevir/Pibrentasvir Real-world Study in China

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

Detailed Description
-----------------
This study is a multi-center, prospective, real-world study, aiming to investigate the use of Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and evaluate its effectiveness and safety across a heterogeneous population in China.Approximately 800 patients will take part in this study, 20 sites will be included which distribute in China's major cities, thus each site will enroll 40 patients.

Official Title
-----------------
The Efficacy, Safety and Long-term Prognosis of Glecaprevir/Pibrentasvir in the Treatment of Chronic Hepatitis C Patients in China--A Real-world Study

Conditions
-----------------
Chronic Hepatitis c

Intervention / Treatment
-----------------
* Drug: Glecaprevir/Pibrentasvir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old Meet the standard of Glecaprevir/Pibrentasvir treatment Exclusion Criteria: Patients have contraindications to Glecaprevir/Pibrentasvir Pregnancy or lactation Malignancy Decompensatory cirrhosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| G/P treatment<br>Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment | Drug: Glecaprevir/Pibrentasvir<br>* Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment<br>* Other names: Mavyret;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SVR 12 | The effectiveness of Glecaprevir/Pibrentasvir treatments and SVR rate 12 weeks after Glecaprevir/Pibrentasvir treatments | 12 weeks after Glecaprevir/Pibrentasvir treatments | 
| progression of Chronic liver disease | Incidence of liver disease progression (such as cirrhosis, decompensation of liver function, liver cancer, liver transplantation, or liver related death) | 5 years after Glecaprevir/Pibrentasvir treatments | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| long term outcome | Assess the duration of the virologic response (5 years) in CHC patients with daas-based regimens who have achieved a sustained virologic response (svr12/24) at 12 or 24 weeks after the end of treatment and analyze the factors influencing the recurrence of HCV | 5 years | 
| HRQOL | To evaluate the impact of DAAs treatment on health-related quality of life (HRQOL) and health status of CHC patients | 5 years |
Study in Subjects Greater Than 40 Years of Age With COPD

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, Phase IIIb, randomized, double-blind, active-controlled, parallel-group, comparative study. The objectives of this study are: To compare the efficacy of tiotropium 18 mcg once daily plus Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg twice daily to tiotropium 18 mcg once daily. To obtain safety data on the use of tiotropium 18 mcg once daily plus FFIS 20 mcg twice daily compared to tiotropium 18 mcg once daily.

Official Title
-----------------
A 6-Week Trial to Compare the Efficacy and Safety of Concomitant Treatment With Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: formoterol fumarate inhalation solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medical diagnosis of COPD Current or prior history of cigarette smoking Exclusion Criteria: Medical diagnosis of asthma Significant condition or disease other than COPD

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: formoterol fumarate inhalation solution|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary efficacy endpoint will be the standardized area under the curve for FEV1 (FEV1 AUC0-3) over the 3-hour assessment period at End Study (Week 6/ET). |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD
Uterine Artery Embolization and Pelvic Floor Symptoms

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine whether women who are already receiving treatment for their fibroids (ie. UAE) demonstrate improvement in urinary symptoms and sexual dysfunction as well.

Official Title
-----------------
Effect of Uterine Artery Embolization on Symptoms of Pelvic Floor Dysfunction

Conditions
-----------------
Leiomyoma, Incontinence, Prolapse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female age 18-80 years symptomatic uterine fibroids scheduled for UAE Negative urine dipstick (negative result = trace or less for leukocytes & nitrites) or negative UA or negative culture (Urine dipstick is performed as standard of care) Available for 12-months of follow-up and able to complete study assessments, per clinician judgment Signed consent form Exclusion Criteria: Age <18 or >80 years women who are unable to read and write English, pregnancy or planned pregnancy in the next 12 months < 6 months postpartum current use of anticholinergic medication, cholinergic agonists, tricyclic antidepressants, or duloxetine - must have been off such drugs for at least 4 weeks women with surgery for urinary incontinence or pelvic organ prolapse in the past 6 months history of bladder or pelvic cancer or pelvic radiation therapy prior augmentation cystoplasty urethral diverticulum, current or repaired.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Uterine artery embolization<br>Women with symptomatic uterine fibroids scheduled for uterine artery embolization | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary symptoms as demonstrated by questionnaires |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sexual dysfunction as defined by questionnaires |  | 1 year |
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: FK962


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject satisfies the criteria for the clinical diagnosis of probable AD Subject has a score =< 4 on the Modified Hachinski Ischemia Scale at the screening visit Exclusion Criteria: Subject has history or evidence of significant neurologic disease other than AD Subject has a history of stroke Subject has been treated for schizophrenia or recurrent mood disorder within the previous three years Subject has a hematologic or solid malignancy diagnosed within five years prior to study entry Subject has medically unstable COPD or asthma Subject has end stage CHF (NYHA Class III or IV) or unstable angina Subject has evidence of significant renal insufficiency Subject has insulin-dependent diabetes mellitus or HbA1C>8.5% at screening

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: FK962|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Validity and Reliability of Vietnamese Version of 17items-Hamilton Depression Rating Scale

Study Overview
=================
Brief Summary
-----------------
this reseach examines the reliability and validity of 17 items- Hamilton Depression rating scale in Vietnamese population, which has been commonly used in clinical depression practice and study.

Detailed Description
-----------------
- Cross-sectional study

Official Title
-----------------
Department of Psychiatry University of Medicine and Pharmacy at Ho Chi Minh City

Conditions
-----------------
Depression, Unipolar

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients accept paticipating in reasearch Exclusion Criteria: patients don't answer full HRDS
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| validity and reliability of Vietnamese version of HDRS -17 | the study measures validity and reliability of Vietnamese version of HDRS -17 | 2020-2021 |
Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare two different types of scopes that can be used for HoLEP. HoLEP is performed through the urethra using a Laser scope to remove obstructing prostate tissue. Laser scopes come in different sizes (diameters).

Official Title
-----------------
Does Sheath Size Matter? Wolf 24 F vs. Storz 28 F Laser Sheath Size for Holmium Laser Enucleation of the Prostate

Conditions
-----------------
Benign Prostatic Hypertrophy

Intervention / Treatment
-----------------
* Device: Richard Wolf 24F Laser scope
* Device: Karl Storz 28F Laser Scope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients Males 18-89 undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms Exclusion Criteria: Patients who lack decisional capacity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: randomized to one of two different types of scopes.
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Richard Wolf 24F Laser scope<br> | Device: Richard Wolf 24F Laser scope<br>* 24F Laser with HoLEP<br>|
| Active Comparator: Karl Storz 28F Laser scope<br> | Device: Karl Storz 28F Laser Scope<br>* 28 F Laser with HoLEP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgery Time difference between the 24F laser scope and the 28F laser scope | comparing operative time between the 24F and the 28F laser scope groups. | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgeon evaluation of Laser scopes flow rate | Internal survey within REDCap to be completed by the surgeon using the scope. The survey will ask the surgeon the following questions after every surgery 1) How was the flow through the scope? a. 1) Poor 2) Problematic 3) Mediocre 4) Adequate 5) Good | Day 0 | 
| Surgeon evaluation of Laser scope visualization | Internal survey within REDCap to be completed by the surgeon using the scope. The survey will ask the surgeon the following questions after every surgery 2) How was the visualization? a. 1) Poor 2) Problematic 3) Mediocre 4) Adequate 5) Good | Day 0 | 
| Surgeon evaluation of Laser scope bladder injury | Internal survey within REDCap to be completed by the surgeon using the scope. The survey will ask the surgeon the following questions after every surgery 3) Did bladder injury occur? a. 1) Yes 2) No | Day 0 |
Comparison of 3 Methods to Diagnose Endolymphatic Hydrops in Meniere's Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare 3 methods for the diagnosis of endolymphatic hydrops (EH) in patients with Meniere's disease: MRI 3 Tesla (to visualise EH directly), and functional explorations, namely electrocochleography and dephasing of acoustic distortion products (which are modified by the EH). The research hypothesis is that the examinations will show agreement in the diagnosis of EH, and that the results obtained (quantitative values) will vary in the same direction over time and during flares of MD.

Official Title
-----------------
Diagnostic Agreement of Electrophysiological Audiovestibular Examinations With Magnetic Resonance Imaging (MRI) of the Inner Ear in Revealing Endolymphatic Hydrops (EH) in Patients With Certain or Probable Meniere's Disease (MD)

Conditions
-----------------
Endolymphatic Hydrops

Intervention / Treatment
-----------------
* Diagnostic Test: MRI 3T


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: persons who have provided written consent persons aged 18 to 75 years persons with certain or probable Meniere's disease according to the international classification AAO-HNS Exclusion Criteria: persons without health insurance cover adults under guardianship persons with a history of hypersensitivity to the active substance or to one of the excipients of the contrast agent used for the MRI or to any gadolinium chelate pregnant or breast-feeding women severe acute or chronic kidney failure other identified causes of cochleo-vestibular syndromes Impossibility to follow-up or carry out any of the examinations necessary for the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Certain or probable Meniere's disease<br> | Diagnostic Test: MRI 3T<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients for whom an endolymphatic hydrops was diagnosed by electrocochleography |  | day one | 
| Number of patients for whom an endolymphatic hydrops was diagnosed by (Dephasing) of acoustic distortion products |  | day one | 
| Number of patients for whom an endolymphatic hydrops was diagnosed by 3T MRI 3T |  | day one |
Acupuncture for the Treatment of Chronic Daily Headaches

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether acupuncture can reduce pain in long-term headache sufferers.

Detailed Description
-----------------
Acupuncture has been shown to reduce the frequency and severity of some types of headaches, but the efficacy of acupuncture for chronic daily headaches has not been studied. The long-term goals of this study are to reduce the symptoms that are associated with recurrent headaches and to collect data that can be used for future acupuncture studies. Participants in this study will be randomly assigned to receive 8 weeks of either standard care or ten acupuncture treatments in addition to medical care. Self-report questionnaires will be used to assess headaches and daily pain severity.

Official Title
-----------------
Acupuncture for the Treatment of Chronic Daily Headaches

Conditions
-----------------
Headache Disorders

Intervention / Treatment
-----------------
* Procedure: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to communicate in English Presence of headache 15 or more days in the past month Exclusion Criteria: Known intracranial mass Recent surgery to the head and neck region

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Acupuncture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Headache, Acupuncture